HOXC8 and lung carcinoma: Especially, we will investigate the potential of using lipid-conjugated or nanoparticle-delivered HOXC8 siRNA to boost the efficacy of immune checkpoint blockers such as anti-PD1 and anti-PD-L1 in LKB-null lung cancer models.